Protein tyrosine phosphatase non-receptor type 1 (PTPN1)

Overview

Protein tyrosine phosphatase non-receptor type 1 (PTPN1), commonly known as protein tyrosine phosphatase 1B (PTP1B), is a non-receptor protein tyrosine phosphatase that functions as a key negative regulator of signaling pathways mediated by receptor tyrosine kinases. In the contexts provided, it is described as a major modulator of insulin and Leptin (LEP) signaling, and therefore as an important molecular target in type 2 diabetes, obesity, and broader metabolic dysfunction. By attenuating these pathways, PTP1B can contribute to insulin resistance and impaired metabolic homeostasis.

Recent research also highlights a more complex role for PTP1B in immune and inflammatory biology. In myeloid cells, it has been linked to monocyte and macrophage activation, with implications for diabetic retinopathy and retinal neurodegeneration. This broader biology has made PTP1B a continuing focus of drug discovery efforts, especially for selective inhibitors that could improve glucose homeostasis and metabolic signaling without unacceptable off-target effects.

Recent Publications Summary

Recent studies have continued to position Protein tyrosine phosphatase non-receptor type 1 (PTPN1/PTP1B) as a therapeutic target in metabolic disease, especially type 2 diabetes and obesity. Several reports focused on identifying small-molecule, natural-product, or peptide-based inhibitors intended to restore insulin and leptin signaling. Flavonoids from Elsholtzia ciliata potently inhibited PTP1B in vitro and improved redox balance and glucose-related signaling in palmitate-treated muscle and liver cell models, with EC2 and EC5 showing the strongest functional effects 42113121May. Similarly, natural products from hemp seed hulls were reported to improve glucose homeostasis by selectively inhibiting PTP1B and re-engaging insulin, leptin, and AMPK pathways 41831381Mar, while stapled lipopeptide analogues of BimBH3 were designed to combine improved proteolytic stability with PTP1B inhibitory activity for diabetes therapy 41831409Mar.

PTPN1 was also pursued as an immuno-oncology target in dual-inhibitor programs and mechanistic studies. A structure-based design campaign identified benzothiophene difluoromethyl phosphonate compounds as potent and selective dual PTPN2/PTPN1 inhibitors, with further optimization improving potency, selectivity, and pharmacokinetic properties; the lead compound induced dose-dependent pSTAT1 in a mouse tumor model and implicated SLC19A1 in cellular uptake 42054654Apr. In related work, researchers used a function-based, iterative screening platform to discover noninhibitory macrocyclic ligands for PTP1B, illustrating a proximity-driven strategy to engage a phosphatase without blocking catalysis 42504525Jul. Another structure-based de novo design study generated dual DPP IV/PTP1B inhibitors, with several lead candidates showing strong predicted binding to PTP1B and supporting the continued exploration of PTP1B in glucose-homeostasis-directed polypharmacology 42378400Jun.

Beyond metabolic disease, PTPN1 has appeared in inflammatory and neurodegenerative contexts. In diabetic mice, myeloid cell-specific PTP1B depletion or pharmacologic inhibition with MSI-1436 prevented early retinal neurodegeneration and associated inflammatory changes in diabetic retinopathy models 42166617May. These findings support a role for myeloid PTP1B in diabetic retinal injury and suggest that targeting the enzyme can alter inflammatory cell activation and tissue outcomes in the diabetic setting 42166617May.

Several recent publications instead centered on SHP2/PTPN11, which is a different phosphatase family member; these studies are included here only because they used phosphatase-targeted strategies relevant to the broader signaling landscape in which PTPN1 participates. SHP2 inhibitors such as I-0436650 and NSC 57774 were shown to suppress MAPK/ERK, AKT, and STAT signaling and reduce tumor growth or cancer-cell proliferation in RAS-driven or gastric cancer models 42593923Aug42531194Jul, and SHP2 was implicated as a downstream component of EGFR/SHP2/SOS1-dependent RAS signaling that contributes to KRAS-inhibitor resistance in pancreatic cancer 42095550May. One study in an obesity-driven leukemia model further linked PTPN11-mutant hematopoiesis with IL-17A-associated immunosuppression and showed benefit from combined GLP-1R agonist and anti-IL-17A therapy 42334870Jun.

What Changes, What Holds

1. PTP1B inhibition is being extended into new inhibitor chemotypes and combination-like pathway restoration strategies
REINFORCES Flavonoids, hemp-seed-derived products, and stapled lipopeptides all point in the same direction as the established account: PTPN1 remains a druggable negative regulator of insulin and leptin signaling in metabolic disease 42113121May41831381Mar41831409Mar. What changes is not the biology but the breadth of chemical space now being used to pursue it, including agents aimed at improving cellular redox state and AMPK-linked metabolic readouts alongside direct PTP1B inhibition.

2. PTP1B is also being leveraged in immuno-oncology and probe-discovery strategies beyond metabolic disease
NEW DIRECTION PTPN1’s established role is as a metabolic and inflammatory regulator, but the baseline does not assign it a cancer-immunotherapy function or a ligand-discovery role that avoids catalytic inhibition. Dual PTPN2/PTPN1 inhibitors with tumor-model activity suggest a translational oncology angle 42054654Apr, while noninhibitory macrocyclic ligands expand the toolkit for engaging PTP1B without shutting down phosphatase activity 42504525Jul. Dual DPP IV/PTP1B design 42378400Jun reinforces metabolic targeting but also supports broader polypharmacology.

3. Myeloid PTP1B is emerging as a driver of diabetic retinal injury rather than only a metabolic brake
NEW DIRECTION The Overview already mentions myeloid-cell involvement in diabetic retinopathy, but the new work sharpens that into a tissue-protective consequence: suppressing myeloid PTP1B alters early retinal neurodegeneration and inflammatory remodeling in diabetic mice 42166617May. This does not overturn the metabolic model; it adds a disease-specific inflammatory mechanism and supports retinal myeloid cells as a tractable compartment for intervention in diabetic complications.

4. SHP2 papers do not change the PTPN1 account
REINFORCES SHP2/PTPN11 studies sit outside the established PTP1B biology and therefore do not revise what is known about PTPN1. Their relevance is contextual only: they show that phosphatase-targeted signaling remains therapeutically active in cancer and immune disease, but they neither contradict nor extend the Overview’s claims about PTP1B 42593923Aug42531194Jul42095550May42334870Jun. As such, they are background for the field, not update material for this entity.

Overview update candidates: PTP1B as a target in myeloid-driven diabetic retinal neurodegeneration; expanded chemical strategies for selective PTP1B inhibition and noninhibitory engagement; oncology-oriented dual PTPN2/PTPN1 inhibitor development.